119 related articles for article (PubMed ID: 19433385)
1. Loving our bones.
Sledge GW
Clin Breast Cancer; 2009 May; 9(2):71. PubMed ID: 19433385
[No Abstract] [Full Text] [Related]
2. Management of bone loss induced by aromatase inhibitors.
Gnant M
Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
[TBL] [Abstract][Full Text] [Related]
3. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Spence MM; Hui RL; Chan J; Schottinger JE
Ann Pharmacother; 2010 Sep; 44(9):1384-8. PubMed ID: 20682850
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors and bisphosphonates reduce deaths from breast cancer, studies show.
Kmietowicz Z
BMJ; 2015 Jul; 351():h4036. PubMed ID: 26209688
[No Abstract] [Full Text] [Related]
5. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
7. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?
Dhesy-Thind SK
J Clin Oncol; 2012 May; 30(13):1408-10. PubMed ID: 22370320
[No Abstract] [Full Text] [Related]
8. Adjuvant therapy of breast cancer - bisphosphonates.
Saarto T
Cancer Treat Res; 2009; 151():163-77. PubMed ID: 19593512
[No Abstract] [Full Text] [Related]
9. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
10. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
Diel I; Aebi S
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
[No Abstract] [Full Text] [Related]
11. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of bone loss associated with breast cancer treatment.
Hadji P
Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in the adjuvant treatment of early breast cancer: conclusion.
Eiermann W
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S16-7. PubMed ID: 20427028
[No Abstract] [Full Text] [Related]
15. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates in adjuvant treatment of early breast cancer.
; Harbeck N; von Minckwitz G; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S1. PubMed ID: 20427026
[No Abstract] [Full Text] [Related]
17. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitor-associated bone loss.
Bryce J; Bauer M; Hadji P
Oncol Nurs Forum; 2011 May; 38(3):273-6. PubMed ID: 21531678
[No Abstract] [Full Text] [Related]
19. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
Junker N; Nielsen DL; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
[No Abstract] [Full Text] [Related]
20. [Effects of zoledronic acid in the treatment of breast cancer].
Chen J; Liu ZY; Zhao LJ
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
[No Abstract] [Full Text] [Related]
[Next] [New Search]